Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1

Niu, Xianli; Nong, Shirong; Zhang, Xiaomin; Li, Xiangyang; Wang, Cheng; Li, Wei; Zhou, Tianhong

doi:10.1039/d0ra00104j

Cited by 1 publication

(1 citation statement)

References 38 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 59 Semaglutide forms a high-affinity non-covalent bond with plasma albumin (> 99%), enhancing drug stability. 49 , 60 , 61 Semaglutide distribution does not include crossing the blood-brain barrier. 62 The main elimination routes of semaglutide are thru the urine and feces.…”

Section: Methodsmentioning

confidence: 99%

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review

Alorfi¹,

Algarni²

2022

CPAA

View full text Add to dashboard Cite

Purpose Obesity and overweight pose a threat to health and are more common than undernutrition among adults. It is categorized by fat accumulation and a body mass index (BMI) of > 30. A significant increase in worldwide obesity has been ongoing over several decades. Over the past few years, several strategies have been followed for weight management and to counteract the increasing prevalence of the disease; however, room for improvement with pharmacological options still exists. This review aimed to digest selected past clinical and experimental studies and understand the role of semaglutide treatment for obesity. Methods Articles related to the clinical uses of semaglutide, mechanism of action, pharmacokinetics, pharmacodynamics, and side effects of the drug were identified. Only studies with human subjects who used Semaglutide for obesity management were included and assessed. Results Semaglutide promotes weight loss via appetite and hunger suppression, decreases energy intake, controls eating, and depresses the relative fondness for fatty, energy-dense foods. Moreover, the relationship between obesity and Semaglutide has been widely investigated, and most studies reveal the efficacy of Semaglutide on weight loss. Overall, the pharmacokinetics of semaglutide shows a drop in glycosylated hemoglobin A1c (HbA1c) and total body weight. The usual adverse effects observed in patients treated with Semaglutide include gastrointestinal adverse events, like nausea, vomiting, diarrhea, constipation, and abdominal cramps. Conclusion The findings from the review suggest that semaglutide appears to be beneficial, most notably in its contribution to weight reduction.

show abstract

Section: Methodsmentioning

confidence: 99%

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review

Alorfi¹,

Algarni²

2022

CPAA

View full text Add to dashboard Cite

show abstract

Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1

Abstract: Currently, the curative effects of polypeptide drugs are often restricted due to the short in vivo duration of action.

Cited by 1 publication

References 38 publications

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review

Contact Info

Product

Resources

About